EPI-141

EPI-141 is an investigational epigenetic gene therapy being developed by Epicrispr Biotechnologies (Epic Bio) for the treatment of Retinitis Pigmentosa 4 (RP4). RP4 is a hereditary form of retinal degeneration typically caused by mutations in the Rhodopsin (RHO) gene. EPI-141 utilizes Epic Bio's proprietary Gene Expression Modulation System (GEMS) platform, which employs a nuclease-deficient Cas9 (dCas9) protein fused to epigenetic modulators to precisely regulate gene expression at the transcriptional level without inducing double-strand DNA breaks. The therapy is delivered via an adeno-associated virus (AAV) vector and is designed to modulate the expression of the target gene to preserve photoreceptor function and prevent vision loss in patients with RP4.